• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DEXIS Attends ADF, Showcases Award-Winning Solutions

    11/28/24 9:30:00 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care
    Get the next $NVST alert in real time by email

    QUAKERTOWN, PA / ACCESSWIRE / November 28, 2024 / The latest AI-powered launches from DEXIS enhance diagnostics and patient care. At ADF, DEXIS showcased its innovative product line, including the new intraoral scanners and imaging products. The conference took place November 26-30 at the Palais des Congrès de Paris in Porte Maillot, France. The company's comprehensive range of award-winning solutions covers a complete digital diagnostic workflow, from intraoral scanning and implant planning to sensors, CBCT, and imaging software. With an expanded portfolio and ecosystem, DEXIS Solutions is designed to accelerate workflows, increase productivity, and improve the patient experience.

    "Our technology makes it easy to organize information and execute treatments, which is at the core of what clinicians expect from us," said DEXIS President, Robert Befidi. "We are connecting and standardizing the implant workflow while also constantly evaluating our efforts to ensure we provide deeper patient insights and flexible, intuitive solutions that reduce complexity. The latest three launches are a good example of our focus on continuous innovation across the ecosystem to deliver diagnostic confidence, productivity, and smart simplicity."

    For many dental professionals, the ADF was the first opportunity to experience the brand new DEXIS ORTHOPANTOMOGRAPH™ OP 3D™ EX and its innovative features that offer expanded 3D diagnostic possibilities. DEXIS solution experts were on hand to provide live demonstrations of key features, including:

    • Tailored images to your diagnostic needs with 66 customizable field of view, from 5 (H) x 5(ø) cm to 10(H) x 15(ø) cm*

    • User friendly 3D acquisition process based on clinical parameters to define and position the field of view

    • Capture high-clarity images while reducing the likelihood for errors through the accuracy and continuity of single-pass capture

    • Solutions to optimize each acquisition to decrease x-ray dose and meet ALARA principle

    • Seamless integration with award-winning AI-powered DTX StudioTM Clinic software & treatment offering expansion

    *10 x 15 cm optional field of view size

    "The new OP 3D™ EX has significantly improved my workflow. The image quality is excellent, the DTX Studio™ Clinic software is easy to use and the image elaboration very precise, allowing me to make quick and accurate diagnoses. With this device, I can work more efficiently and with greater confidence," says Dr. Massimo Saratti, Switzerland.

    The ADF will be an opportunity for dental professionals to discover, among other things, the flagship product of the DEXIS IOS solutions range: the DEXIS IS 3800W wireless scanner, which is aimed at both practitioners who are new to intraoral scanning and experienced users who want more freedom.

    The new intraoral scanning software update offers scan quality and usability improvements as well as clear visualizations of progressive dental issues over time, through a new tool called Oral Compare. Additionally, the software's new integration with SmileFy allows for the ability to simulate treatment outcomes chairside, giving patients further confidence in proposed treatment plans.

    The IS 3800W will increase dental practitioners' efficiency and take their practice to the next level. It offers many benefits, including:

    • Ultra-lightweight (240g) and compact wireless intraoral scanner

    • Ultra-fast impression capture demonstrated in 25 seconds for one arch**

    • Up to one hour of continuous impression capture on a single battery charge

    • No licensing, no additional fees

    • 2-year manufacturer warranty, with the option to extend up to 5 years

    To learn more about DEXIS solutions, visit: https://to.dexis.com/fr-fr/adf-2024

    ** In vitro testing performed on a plaster model.

    About DEXIS

    DEXIS is the global leader in dental imaging. We bring together the most trusted brands in 2D and 3D imaging (such as Gendex™, SOREDEX™, i-CAT™, and Instrumentarium™), intraoral scanning solutions, and diagnostic software, in one connected and AI-powered ecosystem. Our innovative and award-winning technologies use smart simplicity to increase productivity and enhance diagnostic confidence. For more information, visit our page www.dexis.com/fr-fr.

    About Envista Holdings Corporation

    Envista is a globally recognized family of more than 30 trusted dental brands, including DEXIS, Nobel Biocare, Ormco and Kerr, united by a shared purpose: to partner with dental professionals to improve the lives of patients. Envista helps its customers deliver the best possible patient care through innovative dental supplies, solutions, technologies and services. Its comprehensive portfolio, including dental implants and treatment options, orthodontics and digital imaging technologies, covers a wide range of dentists' clinical needs for the diagnosis, treatment and prevention of dental diseases, as well as for the improvement of smile aesthetics. Through the proven methodology of the Envista Business System (EBS), an experienced management team and a strong culture focused on continuous improvement, commitment to innovation and customer satisfaction, Envista has the ability to meet the global needs of dental professionals. Envista is one of the world's largest dental products companies, with significant market positions in some of the most attractive segments of the dental industry. For more information, visit www.envistaco.com.

    .

    Source: DEXIS

    Get the next $NVST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What products did DEXIS launch at the ADF conference?

      DEXIS showcased its innovative product line, including the new intraoral scanners and various imaging products aimed at enhancing diagnostics and patient care.

    • What are some key features of the DEXIS ORTHOPANTOMOGRAPH™ OP 3D™ EX?

      The DEXIS ORTHOPANTOMOGRAPH™ OP 3D™ EX offers features like customizable fields of view, a user-friendly acquisition process, and high-clarity image capture while reducing x-ray dose.

    • What efficiency improvements does the DEXIS IS 3800W wireless scanner provide?

      The new IS 3800W wireless scanner can capture impressions in as fast as 25 seconds and offers up to one hour of continuous capture on a single charge.

    • How does the integration of DTX Studio™ Clinic software benefit dental practitioners?

      The DTX Studio™ Clinic software integrates with the new IS 3800W scanner, enhancing usability and allowing for simulation of treatment outcomes chairside, increasing patient confidence.

    • What is Envista Holdings Corporation known for in the dental industry?

      Envista Holdings Corporation is recognized as a global dental products leader, comprising over 30 trusted dental brands, including DEXIS, and focuses on improving patient lives through innovative dental solutions.

    Recent Analyst Ratings for
    $NVST

    DatePrice TargetRatingAnalyst
    2/6/2026$35.00Market Perform → Outperform
    Leerink Partners
    12/9/2025$24.00Overweight
    Barclays
    5/27/2025$23.00Neutral → Outperform
    Robert W. Baird
    12/4/2024$20.00Underperform
    Mizuho
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    10/8/2024$20.00Equal Weight
    Wells Fargo
    8/8/2024$23.00 → $16.00Overweight → Neutral
    JP Morgan
    4/26/2024$33.00 → $21.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $NVST
    SEC Filings

    View All

    Envista Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Envista Holdings Corp (0001757073) (Filer)

    2/5/26 4:11:14 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Envista Holdings Corporation

    SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)

    1/29/26 12:54:34 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Envista Holdings Corporation

    SCHEDULE 13G/A - Envista Holdings Corp (0001757073) (Subject)

    11/7/25 11:43:00 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Envista Reports Fourth Quarter 2025 Results

    BREA, Calif., Feb. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2025. "With our disciplined focus on Growth, Operations, and People, Q4 2025 marked another quarter of continued progress for Envista," said Paul Keel, CEO.  "We delivered 10.8% core revenue growth and 22% adjusted EBITDA growth in Q425, and 6.5% core revenue growth and 26% EBITDA growth for the full-year 2025.  In the process, we posted positive growth in all major businesses and geographies, made broad-based improvements in employee d

    2/5/26 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Fourth Quarter 2025 Earnings Call

    BREA, Calif., Jan. 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2025 on Thursday, February 5, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y

    1/8/26 4:20:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista to Present at the 44th Annual J.P. Morgan Healthcare Conference

    BREA, Calif., Jan. 7, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 12, 2026, from 3:45 – 4:25 pm PST.  A live audio webcast of the event will be available in the Investors section of the Envista website at https://investors.envistaco.com/. Additionally, a replay of the webcast will be available on the Envista website for 30 days following the presentation. ABOUT ENVISTA HOLDINGS CORPORATION Envista

    1/7/26 4:15:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Keel Paul A

    4 - Envista Holdings Corp (0001757073) (Issuer)

    2/3/26 9:04:09 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Hammes Eric D.

    4 - Envista Holdings Corp (0001757073) (Issuer)

    2/3/26 9:04:15 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President, Diagnostics Befidi Robert

    4 - Envista Holdings Corp (0001757073) (Issuer)

    2/3/26 9:04:25 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Envista upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Envista from Market Perform to Outperform and set a new price target of $35.00

    2/6/26 8:05:48 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Barclays initiated coverage on Envista with a new price target

    Barclays initiated coverage of Envista with a rating of Overweight and set a new price target of $24.00

    12/9/25 8:46:01 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Envista from Neutral to Outperform and set a new price target of $23.00

    5/27/25 9:05:49 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/14/24 4:40:20 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    8/13/24 6:01:10 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

    4 - Envista Holdings Corp (0001757073) (Issuer)

    11/20/23 5:49:32 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Leadership Updates

    Live Leadership Updates

    View All

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Compass Diversified Announces Stephen Keller as Chief Financial Officer

    WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b

    8/26/24 6:00:00 AM ET
    $AVY
    $CODI
    $NVST
    Containers/Packaging
    Consumer Discretionary
    Home Furnishings
    Medical/Dental Instruments

    Envista Holdings Corporation Announces Key Leadership Appointments

    BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an

    7/15/24 4:10:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Financials

    Live finance-specific insights

    View All

    Envista Reports Fourth Quarter 2025 Results

    BREA, Calif., Feb. 5, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2025. "With our disciplined focus on Growth, Operations, and People, Q4 2025 marked another quarter of continued progress for Envista," said Paul Keel, CEO.  "We delivered 10.8% core revenue growth and 22% adjusted EBITDA growth in Q425, and 6.5% core revenue growth and 26% EBITDA growth for the full-year 2025.  In the process, we posted positive growth in all major businesses and geographies, made broad-based improvements in employee d

    2/5/26 4:05:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Schedules Fourth Quarter 2025 Earnings Call

    BREA, Calif., Jan. 8, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its fourth quarter 2025 on Thursday, February 5, 2026. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. Y

    1/8/26 4:20:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    Envista Reports Third Quarter 2025 Results

    BREA, Calif., Oct. 29, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended September 26, 2025. This was another strong quarter for Envista"This was another strong quarter for Envista, with core growth, adjusted EBITDA, and adjusted EPS all ahead of expectations," said Paul Keel, CEO. "We delivered positive growth in all major businesses and once again captured share with Spark aligners, while also turning to profitability in the business. My thanks to our teams around the world for making all this progress possible." Fina

    10/29/25 8:28:00 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    11/8/24 12:09:03 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

    SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

    2/15/24 10:19:33 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Envista Holdings Corporation

    SC 13G - Envista Holdings Corp (0001757073) (Subject)

    2/14/24 4:08:38 PM ET
    $NVST
    Medical/Dental Instruments
    Health Care